8-K: Oruka Therapeutics Reports Positive Phase 2a Psoriasis Trial Data

Oruka Therapeutics announced positive Week 16 results from its Phase 2a EVERLAST-A trial for ORKA-001 in moderate-to-severe psoriasis, showing significant skin clearance and a favorable safety profile.

Summary

• Oruka Therapeutics announced positive interim results from its Phase 2a EVERLAST-A clinical trial for ORKA-001, an anti-IL-23 antibody, in patients with moderate-to-severe plaque psoriasis.
• The trial met its primary endpoint, with 63.5% of patients achieving PASI 100 (complete skin clearance) at Week 16, compared to 4.8% for placebo.
• Key secondary endpoints, including IGA 0 and PASI 90, were also met with high response rates.
• ORKA-001 demonstrated a favorable safety profile, consistent with the IL-23p19 inhibitor class, with no serious treatment-emergent adverse events reported in the ORKA-001 arm.
• Updated Phase 1 pharmacokinetic and pharmacodynamic data suggest the potential for annual dosing of ORKA-001.
• Longer-term data from EVERLAST-A are expected in the second half of 2026, and the Phase 2b EVERLAST-B trial is ongoing with data expected in 2027.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive announcement due to the strong efficacy and safety results in the Phase 2a trial, along with promising data supporting potential annual dosing.

Positives

• ORKA-001 met the primary endpoint of PASI 100 at Week 16, with 63.5% of treated patients achieving complete skin clearance.
• High response rates were observed for key secondary endpoints: 82.5% achieved PASI 90 and 84.1% achieved IGA 0/1.
• The drug was generally well-tolerated, with a safety profile consistent with the IL-23p19 inhibitor class.
• No serious treatment-emergent adverse events (TEAEs) were reported in the ORKA-001 treatment arm.
• No discontinuations due to adverse events were observed.
• Updated Phase 1 PK/PD data support the potential for annual dosing.
• The efficacy results compare favorably to standard of care based on cross-trial comparisons.

Negatives

• The most common treatment-emergent adverse event was upper respiratory tract infection, reported in 19.0% of the ORKA-001 group versus 14.3% for placebo.
• While no serious TEAEs occurred in the ORKA-001 arm, one serious TEAE occurred in the placebo group.

Risks

• The trial is ongoing, and longer-term data, including durability of response and additional safety follow-up, are expected in the second half of 2026.
• The EVERLAST-B trial is designed to evaluate three dose levels and continues to enroll participants with data expected in 2027.
• Forward-looking statements are subject to risks and uncertainties, including those detailed in the company's most recent Annual Report on Form 10-K.

Future Outlook

Longer-term data from the EVERLAST-A trial, including durability of response and additional safety follow-up, are expected in the second half of 2026. The Phase 2b EVERLAST-B trial is ongoing with data expected in 2027. The company aims to achieve a fast-track to Biologics License Application (BLA) submission.

Management Comments

• "These data reached the top end of what we could have expected from ORKA-001 across efficacy, tolerability, and potential for long-lasting response," said Joana Goncalves, MBChB, Chief Medical Officer of Oruka.
• "Were thrilled with the profile that is emerging for this program and are excited to see how the data mature with longer-term follow-up."
• "I want to thank the Oruka team, the EVERLAST-A investigators, and the trial participants for getting this study off to a tremendous start."
• "These data with ORKA-001 are highly compelling," said Dr. Bruce Strober, MD, PhD, Clinical Professor of Dermatology at Yale University School of Medicine and lead investigator for EVERLAST-A.
• "If this type of efficacy and safety profile could be available with dosing once to twice per year, it would represent a major step forward for the field. I could envision this being the preferred product for any patient with moderate-to-severe psoriasis."

Industry Context

StockSavvy.ai notes that Oruka Therapeutics is positioning ORKA-001 as a potentially best-in-class IL-23p19 antibody with the potential for annual dosing, aiming to capture a significant share of the growing psoriasis market, which is projected to reach $39 billion by 2030. The company highlights that new biologics with improved efficacy, like Bimzelx, have successfully entered the market, indicating an opportunity for ORKA-001 if its profile is validated.

Comparison to Industry Standards

• ORKA-001's Week 16 PASI 100 rate of 63.5% is presented as numerically higher than all other IL-23p19 inhibitors based on cross-trial comparisons.
• The efficacy of ORKA-001 is stated to be comparable to the highest reported in plaque psoriasis for any mechanism of action.
• The safety profile is consistent with the IL-23p19 inhibitor class, which is a recognized standard for this therapeutic area.
• The potential for annual dosing, supported by Phase 1 PK/PD data, would represent a significant advancement compared to current IL-23 inhibitors that typically require Q12W dosing (e.g., Skyrizi).

Stakeholder Impact

• Shareholders: Positive results may lead to increased investor confidence and potential stock price appreciation.
• Patients: The data suggest a potential new treatment option with high efficacy and a favorable safety profile, possibly with less frequent dosing.
• Healthcare Providers: The compelling efficacy and potential for annual dosing could make ORKA-001 a preferred treatment option for moderate-to-severe psoriasis.

Next Steps

• Host a conference call and webcast to discuss the EVERLAST-A Phase 2a data.
• Continue enrollment in the EVERLAST-B Phase 2b trial, with data expected in 2027.
• Share longer-term data from EVERLAST-A in the second half of 2026.
• Initiate Phase 2 trials for ORKA-002 in psoriasis/psoriatic arthritis and for ORKA-001 in hidradenitis suppurativa in the second half of 2026.

Key Dates

Recommendation

The strong efficacy (63.5% PASI 100), favorable safety profile, and potential for annual dosing demonstrated in the Phase 2a trial position ORKA-001 as a highly promising candidate in the large psoriasis market. These results, if replicated in further trials, suggest ORKA-001 could become a best-in-class therapy, justifying a strong buy recommendation.

Keywords

Oruka Therapeutics, ORKA-001, Psoriasis, Clinical Trial, Phase 2a, IL-23 Inhibitor, Dermatology, Biotechnology